{
  "id": "suxamethonium_pharmacology_001",
  "updatedAt": "2026-02-18T00:00:00Z",

  "domain": "pharmacology",
  "topicTagIds": ["neuromuscular_blockers", "muscle_relaxants", "pharmacology"],
  "caseId": null,
  "slotType": "any",
  "caseOrder": 0,

  "demographics": {
    "patientAgeGroup": "adult",
    "patientGender": "female"
  },

  "stem": "Dr. {{candidate_name}}, can you tell me about suxamethonium?",

  "prompts": [
    {
      "tier": "recall",
      "text": "What is suxamethonium and how does it work?",
      "expectedKeyFacts": [
        "Depolarising neuromuscular blocker",
        "Two acetylcholine molecules joined back-to-back",
        "Nicotinic acetylcholine receptor agonist at neuromuscular junction",
        "Causes sustained depolarisation — phase I block",
        "Not broken down by acetylcholinesterase",
        "Metabolised by plasma cholinesterase (butyrylcholinesterase)"
      ],
      "timeBudgetSec": 60
    },
    {
      "tier": "mechanism",
      "text": "Describe the pharmacokinetics of suxamethonium.",
      "expectedKeyFacts": [
        "Rapid onset — 30-60 seconds",
        "Short duration — 5-10 minutes",
        "Hydrolysed by plasma cholinesterase to succinylmonocholine then succinic acid",
        "Succinylmonocholine has weak neuromuscular blocking activity",
        "Rapid redistribution from neuromuscular junction",
        "Elimination half-life ~3 minutes",
        "Only ~10% reaches neuromuscular junction"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "application",
      "text": "What are the indications and contraindications for suxamethonium?",
      "expectedKeyFacts": [
        "Indications: rapid sequence induction, difficult airway, laryngospasm",
        "Absolute contraindications: known malignant hyperthermia susceptibility, plasma cholinesterase deficiency",
        "Relative contraindications: hyperkalaemia, burns >24-48 hours old, denervation injuries, neuromuscular disease, penetrating eye injury",
        "Risk of hyperkalaemic cardiac arrest in these conditions",
        "Avoid in children unless emergency airway indication"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "synthesis",
      "text": "A patient has prolonged neuromuscular blockade after suxamethonium. What are the possible causes and how would you manage this?",
      "expectedKeyFacts": [
        "Plasma cholinesterase deficiency — genetic (homozygous, heterozygous) or acquired",
        "Acquired causes: liver disease, malnutrition, pregnancy, organophosphate exposure",
        "Confirm with peripheral nerve stimulator — sustained block",
        "Management: maintain anaesthesia and ventilation until spontaneous recovery",
        "Do NOT use anticholinesterases — ineffective and may prolong block",
        "Fresh frozen plasma in extreme cases (controversial)",
        "Investigate with plasma cholinesterase levels and dibucaine number",
        "Warn patient and family — medic alert, avoid suxamethonium in future"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "evaluation",
      "text": "Why do we still use suxamethonium despite its side effects when rocuronium with sugammadex is available?",
      "expectedKeyFacts": [
        "Faster onset than rocuronium (30-60s vs 60-90s)",
        "Shorter duration — spontaneous recovery in emergency situations",
        "Sugammadex is expensive and may not be immediately available",
        "Suxamethonium relaxes laryngeal muscles more reliably for emergency airway",
        "Decades of clinical experience and familiarity",
        "Acknowledge side effects: hyperkalaemia risk, malignant hyperthermia, bradycardia, muscle pains",
        "Trend towards rocuronium-sugammadex in many centres, but suxamethonium still first-line in many RSI protocols"
      ],
      "timeBudgetSec": 90
    }
  ],

  "rescuePrompt": "Perhaps you could tell me about the side effects of suxamethonium — what concerns do you have when giving it?",

  "keyFacts": [
    "Depolarising neuromuscular blocker",
    "Two acetylcholine molecules linked",
    "Rapid onset (30-60 seconds), short duration (5-10 minutes)",
    "Metabolised by plasma cholinesterase",
    "Phase I depolarising block",
    "Contraindicated in hyperkalaemia, burns, denervation, MH susceptibility",
    "Prolonged block in plasma cholinesterase deficiency",
    "Side effects: bradycardia, hyperkalaemia, muscle pains, raised IOP/ICP/IGP",
    "Triggers malignant hyperthermia",
    "Use in RSI and emergency airway management",
    "Cannot be reversed with anticholinesterases",
    "Dibucaine number identifies genetic variants"
  ],

  "scoringGuidance": {
    "pass": "Correct mechanism (depolarising block), knows rapid onset and short duration, aware of plasma cholinesterase metabolism, identifies key contraindications (burns, hyperkalaemia, MH), describes management of prolonged block; stronger candidates explain dibucaine number and compare with rocuronium-sugammadex strategy",
    "borderline": "Knows suxamethonium is a muscle relaxant and is used for RSI but mechanism unclear, mentions some side effects, vague on contraindications or prolonged block management",
    "fail": "Cannot explain mechanism of action, unaware of plasma cholinesterase metabolism, does not know contraindications, no understanding of hyperkalaemia risk or malignant hyperthermia"
  },

  "author": "SimViva Team",
  "provenance": {
    "generatedBy": "Claude (Anthropic)",
    "generatedAt": "2026-02-18T20:50:00Z",
    "promptVersion": "v1.0.0",
    "sourceMaterial": ["RCoA_Muscle_Relaxants_Guidelines", "BJA_Suxamethonium_2019"],
    "validation": {
      "reviewedBy": "",
      "reviewedAt": "",
      "status": "pending_review",
      "notes": "Awaiting clinical reviewer sign-off."
    }
  },
  "furtherReading": [
    "https://doi.org/10.1093/bja/aep143"
  ],
  "isActive": true
}
